Skip to Content

Potential to become the best treatment for multiple myeloma in history

As a late breaking, the MAIA-study was presented at EHA 2021 by Thierry Facon, Chef du Pôle des Spécialités Médicales et Oncologiques, Hôpital Claude Huriez, and Professor of Haematology in the Department of Haematology, Lille University Hospital, Lille, France. In this MEDtalk present the most important data from MAIA-study. Han also give an answer for the question Is daratumumab-lenalidomide-dexamethasone the best therapy of multiple myeloma in the history?

Avaa artikkeli

Jos olet lääkäri, sairaanhoitaja tai muu terveydenhuollon ammattilainen, voit käyttää koko artikkelia luomalla profiilin BestPractice Nordic -sivustolle.

Back to top